Changes to the landscape of opioid use have occurred throughout the past two decades. Opioid agonist treatment (OAT) plays an important role in reducing opioid-related harms. Yet, people with opioid use disorder (PWOUD) face issues with access and retention. This scoping review sought to provide an up-to-date synthesis on barriers and facilitators to OAT. Ninety-three studies were included. Major barriers included cost, waiting lists, and negative public attitudes toward treatment. Prominent facilitators included OAT education and flexible treatment conditions such as telehealth-delivered OAT. In prison settings, limited support with treatment referral was a barrier. Fear of judgement was a challenge for pregnant people. There was a lack of information on barriers and facilitators specific to PWOUD dealing with chronic pain or mental health comorbidities. Results highlight new challenges in reaching an increasingly heterogeneous PWOUD population. Findings underline the potential for recent advancements in treatment modalities to promote access and retention.
AbrahamA. J.AdamsG. B.BradfordA. C.BradfordW. D. (2019). County‐level access to opioid use disorder medications in medicare Part D (2010‐2015). Health Services Research, 54(2), 390–398. https://doi.org/10.1111/1475-6773.13113
2.
AbuseS.Mental Health Services Administration, C. f. B. H. S., & Quality. (2014). Treatment episode data set (TEDS): 2002–2012. National admissions to substance abuse treatment services. BHSIS series S-71, HHS publication No (SMA) 14-4850. Substance Abuse and Mental Health Services Administration.
AlamF.BarkerP. (2014). Interruption of medication-assisted treatment for opioid dependence: Insights from the UK. Drugs and Alcohol Today.
6.
AllenB.HarocoposA. (2016). Non-prescribed buprenorphine in New York city: Motivations for use, practices of diversion, and experiences of stigma. Journal of Substance Abuse Treatment, 70(Nov), 81–86. https://doi.org/10.1016/j.jsat.2016.08.002
7.
AppelP. W.TsemberisS.JosephH.StefancicA.Lambert-WaceyD. (2012). Housing First for severely mentally ill homeless methadone patients. Journal of Addictive Diseases, 31(3), 270–277. https://doi.org/10.1080/10550887.2012.694602
8.
ArchambaultL.BertrandK.Jutras‐AswadD.MonsonE.TouréE. H.PerreaultM. (2023). People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile‐based approach to care. Drug and Alcohol Review, 42(4), 765–777. https://doi.org/10.1111/dar.13634
9.
ArkseyH.O'MalleyL. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616
10.
Bach‐MortensenA. M.VerboomB. (2020). Barriers and facilitators systematic reviews in health: A methodological review and recommendations for reviewers. Research Synthesis Methods, 11(6), 743–759. https://doi.org/10.1002/jrsm.1447
11.
Bakos-BlockC.LangabeerJ. R.YatscoA.Cardenas-TuranzasM.Champagne-LangabeerT. (2020). Prevalence of mental health disorders among individuals enrolled in an emergency response program for treatment of opioid use disorder. Substance Abuse: Research and Treatment, 14(Dec), 1178221820981998. https://doi.org/10.1177/1178221820981998
12.
BazaziA. R.YokellM.FuJ. J.RichJ. D.ZallerN. D. (2011). Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine, 5(3), 175–180. https://doi.org/10.1097/ADM.0b013e3182034e31
13.
BellJ. (2014). Pharmacological maintenance treatments of opiate addiction. British Journal of Clinical Pharmacology, 77(2), 253–263. https://doi.org/10.1111/bcp.12051
14.
BentzleyB. S.BarthK. S.BackS. E.AronsonG.BookS. W. (2015). Patient perspectives associated with intended duration of buprenorphine maintenance therapy. Journal of Substance Abuse Treatment, 56(Dec), 48–53. https://doi.org/10.1016/j.jsat.2015.04.002
15.
BenyaminaA. (2014). The current status of opioid maintenance treatment in France: A survey of physicians, patients, and out-of-treatment opioid users. International Journal of General Medicine, 7(Sept), 449–457. https://doi.org/10.2147/IJGM.S61014
16.
BessonJ.BeckT.WiesbeckG.HämmigR.KuntzA.AbidS.StohlerR. (2014). Opioid maintenance therapy in Switzerland: An overview of the Swiss IMPROVE study. Swiss Medical Weekly, 144(1314), w13933. https://doi.org/10.4414/smw.2014.13933
17.
BishopL. D.Rosenberg-YungerZ. R. S. (2022). Pharmacists expanded role in providing care for opioid use disorder during COVID-19: A qualitative study exploring pharmacists’ experiences. Drug and Alcohol Dependence, 232(10), 109303. https://doi.org/10.1016/j.drugalcdep.2022.109303
18.
BoeriM.LamonicaA. K.TurnerJ. M.ParkerA.MurphyG.BocconeC. (2021). Barriers and motivators to opioid treatment among suburban women who are pregnant and mothers in caregiver roles. Frontiers in Psychology, 12(Jun), 688429. https://doi.org/10.3389/fpsyg.2021.688429
19.
BogdanowiczK. M.StewartR.BroadbentM.HatchS. L.HotopfM.StrangJ.HayesR. D. (2015). Double trouble: Psychiatric comorbidity and opioid addiction—all-cause and cause-specific mortality. Drug and Alcohol Dependence, 148, 85–92. https://doi.org/10.1016/j.drugalcdep.2014.12.025
20.
BrandtL.UngerA.MoserL.FischerG.JagschR. (2016). Opioid maintenance treatment-a call for a joint European quality care approach. European Addiction Research, 22(1), 36–51. https://doi.org/10.1159/000432395
Brinkley-RubinsteinL.McKenzieM.MacmaduA.LarneyS.ZallerN.DauriaE.RichJ. (2018). A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. Drug and Alcohol Dependence, 184(Mar), 57–63. https://doi.org/10.1016/j.drugalcdep.2017.11.023
23.
BruijnenC. J.DijkstraB. A.WalvoortS. J.MarkusW.VanDerNagelJ. E.KesselsR. P.De JongC. A. (2019). Prevalence of cognitive impairment in patients with substance use disorder. Drug and Alcohol Review, 38(4), 435–442. https://doi.org/10.1111/dar.12922
24.
CalcaterraS. L.LockhartS.CallisterC.HooverK.BinswangerI. A. (2022). Opioid use disorder treatment initiation and continuation: A qualitative study of patients who received addiction consultation and hospital-based providers. Journal of General Internal Medicine, 37(11), 2786–2794. https://doi.org/10.1007/s11606-021-07305-3
25.
CarewA. M.ComiskeyC. (2018a). Rising incidence of ageing opioid users within the EU wide treatment demand indicator; the Irish opioid epidemic from 1996 to 2014. Drug and Alcohol Dependence, 192(Nov), 329–337. https://doi.org/10.1016/j.drugalcdep.2018.08.031
26.
CarewA. M.ComiskeyC. (2018b). Treatment for opioid use and outcomes in older adults: A systematic literature review. Drug and Alcohol Dependence, 182(Jan), 48–57. https://doi.org/10.1016/j.drugalcdep.2017.10.007
27.
ChatterjeeA.YuE. J.TishbergL. (2018). Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family. Drug and Alcohol Dependence, 188(Jul), 161–168. https://doi.org/10.1016/j.drugalcdep.2018.04.012
28.
CiceroT. J.EllisM. S.SurrattH. L.KurtzS. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71(7), 821–826. https://doi.org/10.1001/jamapsychiatry.2014.366
29.
ClaffeyC.CrowleyD.MacLachlanM.Van HoutM. C. (2017). Exploring Irish travellers’ experiences of opioid substitute treatment: A phenomenological study. Heroin Addiction and Related Clinical Problems, 19(6), 12. https://www.drugsandalcohol.ie/27566/
30.
CoraceK.SuschinskyK.WymanJ.LeeceP.CraggS.KonefalS.PanaP.BarrassS.PorathA.HuttonB. (2022). Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing. International Journal of Drug Policy, 102(Apr), 103573. https://doi.org/10.1016/j.drugpo.2021.103573
31.
CoyleY. M.BattlesJ. (1999). Using antecedents of medical care to develop valid quality of care measures. International Journal for Quality in Health Care: Journal of the International Society for Quality in Health Care, 11(1), 5–12. https://doi.org/10.1093/intqhc/11.1.5
32.
CrimeU. N. O. o. D. a. (2021). World drug report. UNO.
33.
CseteJ.CataniaH. (2013). Methadone treatment providers’ views of drug court policy and practice: A case study of New York state. Harm Reduction Journal, 10(1), 35–39. https://doi.org/10.1186/1477-7517-10-35
34.
DamonW.SmallW.AndersonS.MaherL.WoodE.KerrT.McNeilR. (2017). Crisis’ and ‘everyday’initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug and Alcohol Review, 36(2), 253–260. https://doi.org/10.1111/dar.12411
35.
DarkerC. D.HoJ.KellyG.WhistonL.BarryJ. (2016). Demographic and clinical factors predicting retention in methadone maintenance: Results from an Irish cohort. Irish Journal of Medical Science, 185(2), 433–441. https://doi.org/10.1007/s11845-015-1314-5
36.
DavidA. R.SianC. R.GebelC. M.LinasB. P.SametJ. H.Sprague MartinezL. S.MuroffJ.BernsteinJ. A.AssoumouS. A. (2022). Barriers to accessing treatment for substance use after inpatient managed withdrawal (detox): A qualitative study. Journal of Substance Abuse Treatment, 142(Nov), 108870. https://doi.org/10.1016/j.jsat.2022.108870
37.
DeeringD. E.SheridanJ.SellmanJ. D.AdamsonS. J.PooleyS.RobertsonR.HendersonC. (2011). Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addictive Behaviors, 36(6), 636–642. https://doi.org/10.1016/j.addbeh.2011.01.004
D’OnofrioG.O’ConnorP. G.PantalonM. V.ChawarskiM. C.BuschS. H.OwensP. H.BernsteinS. L.FiellinD. A. (2015). Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. JAMA, 313(16), 1636–1644. https://doi.org/10.1001/jama.2015.3474
40.
DufortA.SamaanZ. (2021). Problematic opioid use among older adults: Epidemiology, adverse outcomes and treatment considerations. Drugs & Aging, 38(12), 1043–1053. https://doi.org/10.1007/s40266-021-00893-z
41.
EiblJ. K.MorinK.LeinonenE.MarshD. C. (2017). The state of opioid agonist therapy in Canada 20 years after federal oversight. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 62(7), 444–450. https://doi.org/10.1177/0706743717711167
42.
EvansE. A.YooC.HuangD.SaxonA. J.HserY.-I. (2019). Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 106(Nov), 19–28. https://doi.org/10.1016/j.jsat.2019.08.002
43.
FinlayA. K.MorseE.StimmelM.TaylorE.TimkoC.HarrisA. H.SmelsonD.YuM.Blue-HowellsJ.BinswangerI. A. (2020). Barriers to medications for opioid use disorder among veterans involved in the legal system: A qualitative study. Journal of General Internal Medicine, 35(9), 2529–2536. https://doi.org/10.1007/s11606-020-05944-6
44.
FortneyJ. C.BurgessJ. F.BosworthH. B.BoothB. M.KaboliP. J. (2011). A re-conceptualization of access for 21st century healthcare. Journal of General Internal Medicine, 26(Suppl 2), 639–647. https://doi.org/10.1007/s11606-011-1806-6
45.
FoxA. D.ChamberlainA.SohlerN. L.FrostT.CunninghamC. O. (2015). Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. Journal of Substance Abuse Treatment, 48(1), 112–116. https://doi.org/10.1016/j.jsat.2014.07.015
46.
FoxA. D.MaradiagaJ.WeissL.SanchezJ.StarrelsJ. L.CunninghamC. O. (2015). Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder. Addiction Science & Clinical Practice, 10(1), 2–9. https://doi.org/10.1186/s13722-014-0023-0
47.
FrankD.Mateu-GelabertP.PerlmanD. C.WaltersS. M.CurranL.GuarinoH. (2021). “It’s like ‘liquid handcuffs”: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients’ lives. Harm Reduction Journal, 18(1), 88. https://doi.org/10.1186/s12954-021-00535-y
48.
FuJ. J.ZallerN. D.YokellM. A.BazaziA. R.RichJ. D. (2013). Forced withdrawal from methadone maintenance therapy in criminal justice settings: A critical treatment barrier in the United States. Journal of Substance Abuse Treatment, 44(5), 502–505. https://doi.org/10.1016/j.jsat.2012.10.005
49.
GaetaM.BeitelM.OberleitnerL. M.OberleitnerD. E.MaddenL. M.TamberelliJ. F.BarryD. T. (2020). Correlates of homelessness among patients in methadone maintenance treatment. Medical Care, 58(11), 1030–1034. https://doi.org/10.1097/MLR.0000000000001414
50.
GallagherJ. R.EstreetA.NordbergA.ZongroneC.MinasianR. M.SzymanowskiS. (2022). The interplay between women, opioid use disorder, medication-assisted treatment (MAT), and drug court: A qualitative study. Journal of Human Behavior in the Social Environment, 33(5), 647–662. https://doi.org/10.1080/10911359.2022.2077500
51.
GauthierG.EiblJ. K.MarshD. C. (2018). Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug and Alcohol Dependence, 191(Oct), 1–5. https://doi.org/10.1016/j.drugalcdep.2018.04.029
52.
GiangV.ThulienM.McNeilR.SedgemoreK.AndersonH.FastD. (2020). Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis. SSM - population health, 11(Aug), 100609. https://doi.org/10.1016/j.ssmph.2020.100609
53.
GlowackiK.DuncanM. J.GainforthH.FaulknerG. (2017). Barriers and facilitators to physical activity and exercise among adults with depression: A scoping review. Mental Health and Physical Activity, 13(Oct), 108–119. https://doi.org/10.1016/j.mhpa.2017.10.001
54.
GordonM. S.KinlockT. W.SchwartzR. P.FitzgeraldT. T.O’GradyK. E.VocciF. J. (2014). A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry. Drug and Alcohol Dependence, 142(Sept), 33–40. https://doi.org/10.1016/j.drugalcdep.2014.05.011
55.
GordonM. S.KinlockT. W.SchwartzR. P.O’GradyK. E.FitzgeraldT. T.VocciF. J. (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug and Alcohol Dependence, 172(Mar), 34–42. https://doi.org/10.1016/j.drugalcdep.2016.11.037
56.
GraffF. S.MorganT. J.EpsteinE. E.McCradyB. S.CookS. M.JensenN. K.KellyS. (2009). Engagement and retention in outpatient alcoholism treatment for women. American Journal on Addictions, 18(4), 277–288. https://doi.org/10.1080/10550490902925540
57.
GryczynskiJ.MitchellS. G.JaffeJ. H.O’GradyK. E.OlsenY. K.SchwartzR. P. (2014). Leaving buprenorphine treatment: Patients' reasons for cessation of care. Journal of Substance Abuse Treatment, 46(3), 356–361. https://doi.org/10.1016/j.jsat.2013.10.004
58.
GuarinoH.AcostaM.MarschL. A.XieH.Aponte-MelendezY. (2016). A mixed-methods evaluation of the feasibility, acceptability, and preliminary efficacy of a mobile intervention for methadone maintenance clients. Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors, 30(1), 1–11. https://doi.org/10.1037/adb0000128
59.
HadlandS. E.ParkT. W.BagleyS. M. (2018). Stigma associated with medication treatment for young adults with opioid use disorder: A case series. Addiction Science & Clinical Practice, 13(1), 1–4. https://doi.org/10.1186/s13722-018-0116-2
60.
HallN. Y.LeL.MajmudarI.MihalopoulosC. (2021). Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug and Alcohol Dependence, 221(Apr), 108651. https://doi.org/10.1016/j.drugalcdep.2021.108651
61.
HanB.JonesC. M.EinsteinE. B.ComptonW. M. (2021). Trends in and characteristics of buprenorphine misuse among adults in the US. JAMA Network Open, 4(10), Article e2129409. https://doi.org/10.1001/jamanetworkopen.2021.29409
62.
HardenA.GarciaJ.OliverS.ReesR.ShepherdJ.BruntonG.OakleyA. (2004). Applying systematic review methods to studies of people’s views: An example from public health research. Journal of Epidemiology & Community Health, 58(9), 794–800. https://doi.org/10.1136/jech.2003.014829
HenniganK.CorriganN.KilleenN.ScullyM.KeenanE. (2021). Response of tertiary addictions services to opioid dependence during the COVID-19 pandemic. Irish Journal of Psychological Medicine, 38(4), 301–306. https://doi.org/10.1017/ipm.2021.8
65.
HewellV. M.VasquezA. R.RivkinI. D. (2017). Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study. Substance Abuse Treatment, Prevention, and Policy, 12(1), 3–10. https://doi.org/10.1186/s13011-016-0085-y
66.
HirchakK. A.MurphyS. M. (2017). Assessing differences in the availability of opioid addiction therapy options: Rural versus urban and American Indian reservation versus nonreservation. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 33(1), 102–109. https://doi.org/10.1111/jrh.12178
67.
HserY.-I.MooneyL. J.SaxonA. J.MiottoK.BellD. S.HuangD. (2017). Chronic pain among patients with opioid use disorder: Results from electronic health records data. Journal of Substance Abuse Treatment, 77(Jun), 26–30. https://doi.org/10.1016/j.jsat.2017.03.006
68.
HsuY.-J.MarstellerJ. A.KachurS. G.FingerhoodM. I. (2019). Integration of buprenorphine treatment with primary care: Comparative effectiveness on retention, utilization, and cost. Population Health Management, 22(4), 292–299. https://doi.org/10.1089/pop.2018.0163
69.
HumphreysK.ShoverC. L.AndrewsC. M.BohnertA. S.BrandeauM. L.CaulkinsJ. P.ChenJ. H.CuéllarM.-F.HurdY. L.JuurlinkD. N.KohH. K.KrebsE. E.LembkeA.MackeyS. C.Larrimore OuelletteL.SuffolettoB.TimkoC. (2022). Responding to the opioid crisis in north America and beyond: Recommendations of the stanford–lancet commission. Lancet (London, England), 399(10324), 555–604. https://doi.org/10.1016/S0140-6736(21)02252-2
70.
JeskeC. P.O’ByrneP. (2019). Perceptions and experiences of methadone maintenance treatment: A qualitative descriptive research study. Journal of Addictions Nursing, 30(4), 248–253. https://doi.org/10.1097/JAN.0000000000000307
71.
JonesC. M.ChristensenA.GladdenR. M. (2017). Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug and Alcohol Dependence, 176(Jul), 89–95. https://doi.org/10.1016/j.drugalcdep.2017.03.011
72.
KahnL. S.WozniakM. L.DoscherT.MooreC.VestB. M. (2022). Treatment experiences among people who use opioids: A social ecological approach. Qualitative Health Research, 32(8-9), 1386–1398. https://doi.org/10.1177/10497323221104315
73.
KattakuzhyS.RosenthalE. (2021). Expanding the evidence on integrated opioid use disorder and infectious disease care. Journal of Addiction Medicine, 15(6), 452–453. https://doi.org/10.1097/ADM.0000000000000802
74.
KennedyA. J.WesselC. B.LevineR.DownerK.RaymondM.OsakueD.HassanI.MerlinJ. S.LiebschutzJ. M. (2022). Factors associated with long-term retention in buprenorphine-based addiction treatment programs: A systematic review. Journal of General Internal Medicine, 37(2), 332–340. https://doi.org/10.1007/s11606-020-06448-z
75.
KhanA.KhanQ.KolbE. (2021). Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes. Journal of Substance Abuse Treatment, 123(Apr), 108256. https://doi.org/10.1016/j.jsat.2020.108256
76.
KingZ.KramerC.LatkinC.SufrinC. (2021). Access to treatment for pregnant incarcerated people with opioid use disorder: Perspectives from community opioid treatment providers. Journal of Substance Abuse Treatment, 126(Jul), 108338. https://doi.org/10.1016/j.jsat.2021.108338
77.
KlimasJ.HamiltonM.-A.GorfinkelL.AdamA.CullenW.WoodE. (2021). Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials. Systematic Reviews, 10(1), 1–12. https://doi.org/10.1186/s13643-021-01764-9
78.
KrawczykN.FawoleA.YangJ.TofighiB. (2021). Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: A scoping review. Addiction Science & Clinical Practice, 16(68), 15–68. https://doi.org/10.1186/s13722-021-00275-1
79.
LaiS.LiE.SilverioA.DeBatesR.KellyE. L.WeinsteinL. C. (2021). “It’s a place that gives me hope”: A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center. Substance Abuse, 42(4), 858–864. https://doi.org/10.1080/08897077.2021.1876202
80.
LaphamG.BoudreauD. M.JohnsonE. A.BobbJ. F.MatthewsA. G.McCormackJ.LiuD.SametJ. H.SaxonA. J.CampbellC. I.GlassJ. E.RossomR. C.MurphyM. T.BinswangerI. A.YarboroughB. J. H.BradleyK. A.PROUD Collaborative Investigators. (2020). Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug and Alcohol Dependence, 207(Feb), 107732. https://doi.org/10.1016/j.drugalcdep.2019.107732
81.
LaranceB.CampbellG.MooreT.NielsenS.BrunoR.LintzerisN.CohenM.HallW.MattickR.O’DonnellC.DegenhardtL. (2019). Concerns and help-seeking among patients using opioids for management of chronic noncancer pain. Pain Medicine, 20(4), 758–769. https://doi.org/10.1093/pm/pny078
82.
LeeC. S.RosalesR.SteinM. D.NichollsM.O’ConnorB. M.Loukas RyanV.DavisE. A. (2019). Brief report: Low‐barrier buprenorphine initiation predicts treatment retention among latinx and non‐latinx primary care patients. American Journal on Addictions, 28(5), 409–412. https://doi.org/10.1111/ajad.12925
83.
LevacD.ColquhounH.O’BrienK. K. (2010). Scoping studies: Advancing the methodology. Implementation Science, 5(1), 1–9. https://doi.org/10.1186/1748-5908-5-69
84.
LevesqueJ.-F.HarrisM. F.RussellG. (2013). Patient-centred access to health care: Conceptualising access at the interface of health systems and populations. International Journal for Equity in Health, 12(1), 18–19. https://doi.org/10.1186/1475-9276-12-18
85.
LockardR.PriestK. C.GreggJ.BuchheitB. M. (2022). A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Substance Abuse, 43(1), 1150–1157. https://doi.org/10.1080/08897077.2022.2060447
86.
LucasG. M.ChaudhryA.HsuJ.WoodsonT.LauB.OlsenY.KerulyJ. C.FiellinD. A.FinkelsteinR.Barditch-CrovoP.CookK.MooreR. D. (2010). Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Annals of Internal Medicine, 152(11), 704–711. https://doi.org/10.7326/0003-4819-152-11-201006010-00003
87.
MacArthurG. J.MinozziS.MartinN.VickermanP.DerenS.BruneauJ.DegenhardtL.HickmanM. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. Bmj, 345(Oct), Article e5945. https://doi.org/10.1136/bmj.e5945
88.
MackeyK.VeazieS.AndersonJ.BourneD.PetersonK. (2020). Barriers and facilitators to the use of medications for opioid use disorder: A rapid review. Journal of General Internal Medicine, 35(Suppl 3), 954–963. https://doi.org/10.1007/s11606-020-06257-4
89.
MaddenE. F.ChristianB. T.LagisettyP. A.RayB. R.SulzerS. H. (2021). Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug and Alcohol Dependence, 228(Nov), 109100. https://doi.org/10.1016/j.drugalcdep.2021.109100
90.
MaglioneM. A.RaaenL.ChenC.AzharG.ShahidiniaN.ShenM.MaksabedianE.ShanmanR. M.NewberryS.HempelS. (2018). Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. Journal of Substance Abuse Treatment, 89(Jun), 28–51. https://doi.org/10.1016/j.jsat.2018.03.001
91.
MainaG.MarshallK.SherstobitofJ. (2021). Untangling the complexities of substance use initiation and recovery: Client reflections on opioid use prevention and recovery from a social-ecological perspective. Substance Abuse: Research and Treatment, 15(Oct), 11782218211050372. https://doi.org/10.1177/11782218211050372
92.
MarkT. L.ParishW. J.ZarkinG. A. (2020). Association of formulary prior authorization policies with buprenorphine-naloxone prescriptions and hospital and emergency department use among medicare beneficiaries. JAMA Network Open, 3(4), Article e203132. https://doi.org/10.1001/jamanetworkopen.2020.3132
93.
MartinR. A.GreskoS. A.Brinkley-RubinsteinL.SteinL.ClarkeJ. G. (2019). Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Preventive Medicine, 128(Nov), 105766. https://doi.org/10.1016/j.ypmed.2019.105766
94.
MartinS. A.ChiodoL. M.BosseJ. D.WilsonA. (2018). The next stage of buprenorphine care for opioid use disorder. Annals of Internal Medicine, 169(9), 628–635. https://doi.org/10.7326/M18-1652
95.
MathersB. M.DegenhardtL.AliH.WiessingL.HickmanM.MattickR. P.MyersB.AmbekarA.StrathdeeS. A.2009 Reference Group to the UN on HIV and Injecting Drug Use. (2010). HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet (London, England), 375(9719), 1014–1028. https://doi.org/10.1016/S0140-6736(10)60232-2
96.
MaysN.PopeC.PopayJ. (2005). Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. Journal of health services research & policy, 10(Suppl 1), 6–20. https://doi.org/10.1258/1355819054308576
97.
McAllisterA.FritzellS.AlmrothM.Harber-AschanL.LarssonS.BurströmB. (2018). How do macro-level structural determinants affect inequalities in mental health? a systematic review of the literature. International Journal for Equity in Health, 17(1), 1–4. https://doi.org/10.1186/s12939-018-0879-9
98.
McLeanK.KavanaughP. R. (2019). “They’re making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion. International Journal of Drug Policy, 71(Sept), 118–124. https://doi.org/10.1016/j.drugpo.2019.06.019
99.
McNeilR.KerrT.AndersonS.MaherL.KeewatinC.MilloyM.WoodE.SmallW. (2015). Negotiating structural vulnerability following regulatory changes to a provincial methadone program in vancouver, Canada: A qualitative study. Social Science & Medicine, 133(May), 168–176. https://doi.org/10.1016/j.socscimed.2015.04.008
100.
MendellA.VannabouathongC.LeK.DyrdaP. (2023). Utilization of opioid agonist therapies in Canada. Canadian Journal of Health Technologies, 3(8), 1–36. https://doi.org/10.51731/cjht.2023.714
101.
MiottoK.HillhouseM.DonovickR.Cunningham-RathnerJ.CharuvastraC.TorringtonM.EsagoffA. E.LingW. (2012). Comparison of buprenorphine treatment for opioid dependence in 3 settings. Journal of Addiction Medicine, 6(1), 68–76. https://doi.org/10.1097/ADM.0b013e318233d621
102.
MitchellS. G.MoriokaR.ReisingerH. S.PetersonJ. A.KellyS. M.AgarM. H.BrownB. S.O'GradyK. E.SchwartzR. P. (2011). Redefining retention: Recovery from the patient's perspective. Journal of Psychoactive Drugs, 43(2), 99–107. https://doi.org/10.1080/02791072.2011.587392
103.
MojtabaiR.MauroC.WallM. M.BarryC. L.OlfsonM. (2019). The Affordable Care Act and opioid agonist therapy for opioid use disorder. Psychiatric Services, 70(7), 617–620. https://doi.org/10.1176/appi.ps.201900025
104.
MooreD. J.GoyalD.RodriguezL. (2021). Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program. Journal of Addictions Nursing, 32(3), 205–210. https://doi.org/10.1097/JAN.0000000000000419
105.
MooreK. E.OberleitnerL.SmithK. M.MaurerK.McKeeS. A. (2018). Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared with forced withdrawal. Journal of Addiction Medicine, 12(2), 156–162. https://doi.org/10.1097/ADM.0000000000000381
106.
MooreS. K.GuarinoH.MarschL. A. (2014). “This is not who I want to be:” Experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment. Substance Use & Misuse, 49(3), 303–314. https://doi.org/10.3109/10826084.2013.832328
107.
MunnZ.PetersM. D.SternC.TufanaruC.McArthurA.AromatarisE. (2018). Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Medical Research Methodology, 18(1), 143–147. https://doi.org/10.1186/s12874-018-0611-x
108.
MuthulingamD.BiaJ.MaddenL. M.FarnumS. O.BarryD. T.AlticeF. L. (2019). Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal of Substance Abuse Treatment, 100(May), 18–28. https://doi.org/10.1016/j.jsat.2019.01.019
109.
NotleyC.BlythA.MaskreyV.CraigJ.HollandR. (2013). The experience of long-term opiate maintenance treatment and reported barriers to recovery: A qualitative systematic review. European Addiction Research, 19(6), 287–298. https://doi.org/10.1159/000346674
110.
O'ByrneP.Jeske PearsonC. (2019). Methadone maintenance treatment as social control: Analyzing patient experiences. Nursing Inquiry, 26(2), Article e12275. https://doi.org/10.1111/nin.12275
111.
OECD. (2019). Addressing problematic opioid use in OECD countries. OECD Health Policy Studies.
112.
PasmanE.KollinR.BromanM.LeeG.AgiusE.ListerJ. J.BrownS.ReskoS. M. (2022). Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. Addiction Science & Clinical Practice, 17(1), 35. https://doi.org/10.1186/s13722-022-00316-3
113.
PatrickS. W.MartinP. R.ScottT. A.Michael RichardsM.CooperW. O. (2018). Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states. Substance Abuse.
114.
PayneB. E.KleinJ. W.SimonC. B.JamesJ. R.JacksonS. L.MerrillJ. O.ZhuangR.TsuiJ. I. (2019). Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug and Alcohol Dependence, 200(Jul), 71–77. https://doi.org/10.1016/j.drugalcdep.2019.03.009
115.
PerreaultM.ArchambaultL. (2017). Requis de services en matière de traitement des troubles liés à l’usage d’opioïdes sur l’île de Montréal. Centre de recherche et d’aide pour narcomanes (Cran), Centre universitaire de santé et de services sociaux de l’Ouest-de-l’île-de-Montréal. CRAN.
116.
PetersonJ. A.SchwartzR. P.MitchellS. G.ReisingerH. S.KellyS. M.O’GradyK. E.BrownB. S.AgarM. H. (2010). Why don’t out-of-treatment individuals enter methadone treatment programmes?International Journal of Drug Policy, 21(1), 36–42. https://doi.org/10.1016/j.drugpo.2008.07.004
117.
PhillipsJ. K.FordM. A.BonnieR. J. (2017). Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. National Academies Press.
118.
PilarinosA.KwaY.JoeR.ThulienM.BuxtonJ. A.DeBeckK.FastD. (2022). Navigating opioid agonist therapy among young people who use illicit opioids in vancouver, Canada. International Journal of Drug Policy, 107(Sept), 103773. https://doi.org/10.1016/j.drugpo.2022.103773
119.
PlattL.MinozziS.ReedJ.VickermanP.HaganH.FrenchC.JordanA.DegenhardtL.HopeV.HutchinsonS.MaherL.PalmateerN.TaylorA.BruneauJ.HickmanM. (2018). Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a cochrane review and meta‐analysis. Addiction, 113(3), 545–563. https://doi.org/10.1111/add.14012
RayV.WaiteM. R.SpexarthF. C.KormanS.BergetS.KodaliS.KressD.GuentherN.MurthyV. S. (2020). Addiction management in hospitalized patients with intravenous drug use–associated infective endocarditis. Psychosomatics, 61(6), 678–687. https://doi.org/10.1016/j.psym.2020.06.019
122.
ReesJ.GarciaG. (2019). Clinic payment options as a barrier to accessing medication-assisted treatment for opioid use in Albuquerque, New Mexico. Addictive Disorders & Their Treatment, 18(4), 246–248. https://doi.org/10.1097/adt.0000000000000175
123.
RichertT.JohnsonB. (2015). Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: The case of Sweden. Harm Reduction Journal, 12(1), 1–14. https://doi.org/10.1186/s12954-015-0037-2
124.
RoyP. J.ChoiS.BernsteinE.WalleyA. Y. (2020). Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. Journal of Substance Abuse Treatment, 114(Jul), 108011. https://doi.org/10.1016/j.jsat.2020.108011
125.
RoyP. J.PriceR.ChoiS.WeinsteinZ. M.BernsteinE.CunninghamC. O.WalleyA. Y. (2021). Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug and Alcohol Dependence, 224(Jul), 108703. https://doi.org/10.1016/j.drugalcdep.2021.108703
126.
RussellC.NafehF.PangM.MacDonaldS. F.DerkzenD.RehmJ.FischerB. (2022). Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in ontario, Canada: A mixed-methods study. BMC Public Health, 22(1), 436. https://doi.org/10.1186/s12889-022-12685-0
127.
RussellC.PangM.NafehF.Farrell MacdonaldS.DerkzenD.RehmJ.FischerB. (2022). Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. International Journal of Qualitative Studies on Health and Well-Being, 17(1), 2094111. https://doi.org/10.1080/17482631.2022.2094111
128.
SantoT.CampbellG.GisevN.Martino-BurkeD.WilsonJ.Colledge-FrisbyS.ClarkB.TranL. T.DegenhardtL. (2022). Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug and Alcohol Dependence, 238(Sept), 109551. https://doi.org/10.1016/j.drugalcdep.2022.109551
SchulerM. S.SchellT. L.WongE. C. (2021). Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018. Drug and Alcohol Dependence, 221(Apr), 108588. https://doi.org/10.1016/j.drugalcdep.2021.108588
131.
SchwartzR.KellyS.MitchellS.O’GradyK.SharmaA.JaffeJ. (2020). Methadone treatment of arrestees: A randomized clinical trial. Drug and Alcohol Dependence, 206(Jan), 107680. https://doi.org/10.1016/j.drugalcdep.2019.107680
132.
ScorsoneK. L.HaozousE. A.HayesL.CoxK. J. (2020). Overcoming barriers: Individual experiences obtaining medication-assisted treatment for opioid use disorder. Qualitative Health Research, 30(13), 2103–2117. https://doi.org/10.1177/1049732320938689
133.
ShoffC.YangT.-C.ShawB. A. (2021). Trends in opioid use disorder among older adults: Analyzing medicare data, 2013–2018. American Journal of Preventive Medicine, 60(6), 850–855. https://doi.org/10.1016/j.amepre.2021.01.010
134.
SilversteinS. M.DaniulaityteR.MillerS. C.MartinsS. S.CarlsonR. G. (2020). On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug and Alcohol Dependence, 210(May), 107958. https://doi.org/10.1016/j.drugalcdep.2020.107958
135.
SkidmoreC. R.KaufmanE. A.CrowellS. E. (2016). Substance use among college students. Child and adolescent psychiatric clinics of North America, 25(4), 735–753. https://doi.org/10.1016/j.chc.2016.06.004
136.
SmithT.McNeilK.MitchellR.BoyleB.RiesN. (2019). A study of macro-meso-and micro-barriers and enablers affecting extended scopes of practice: The case of rural nurse practitioners in Australia. BMC Nursing, 18(1), 12–14. https://doi.org/10.1186/s12912-019-0337-z
137.
SocíasM. E.WoodE.KerrT.NolanS.HayashiK.NosovaE.MontanerJ.MilloyM.-J. (2018). Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006–2016. Drug and Alcohol Dependence, 189(Aug), 90–95. https://doi.org/10.1016/j.drugalcdep.2018.04.026
138.
SohlerN.WeissL.EganJ. E.LopezC.FavaroJ.CorderoR.CunninghamC. (2013). Consumer attitudes about opioid addiction treatment: A focus group study in New York city. Journal of opioid management, 9(2), 111–119. https://doi.org/10.5055/jom.2013.0152
139.
SordoL.BarrioG.BravoM. J.IndaveB. I.DegenhardtL.WiessingL.FerriM.Pastor-BarriusoR. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. Bmj, 357(Mar), j1550. https://doi.org/10.1136/bmj.j1550
140.
SousaJ. L.RajaP.HuskampH. A.MehrotraA.BuschA. B.BarnettM. L.Uscher-PinesL. (2022). Perspectives of patients receiving telemedicine services for opioid use disorder treatment: A qualitative analysis of user experiences. Journal of Addiction Medicine, 16(6), 702–708. https://doi.org/10.1097/ADM.0000000000001006
141.
StrangJ.VolkowN. D.DegenhardtL.HickmanM.JohnsonK.KoobG. F.MarshallB. D.TyndallM.WalshS. L. (2020). Opioid use disorder. Nature Reviews Disease Primers, 6(1), 3–28. https://doi.org/10.1038/s41572-019-0137-5
142.
StrikeC.MillsonM.HopkinsS.SmithC. (2013). What is low threshold methadone maintenance treatment?International Journal of Drug Policy, 24(6), e51–e56. https://doi.org/10.1016/j.drugpo.2013.05.005
143.
SwartzN.AdnanT.PeréaF.BaggettT. P.ChatterjeeA. (2022). “Sick and tired of being sick and tired”: Exploring initiation of medications for opioid use disorder among people experiencing homelessness. Journal of Substance Abuse Treatment, 138(Jul), 108752. https://doi.org/10.1016/j.jsat.2022.108752
144.
SyvertsenJ. L.ToneffH.HowardH.SpadolaC.MaddenD.ClappJ. (2021). Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio. Drug and Alcohol Dependence, 222(May), 108677. https://doi.org/10.1016/j.drugalcdep.2021.108677
145.
Titus-GloverD.ShayaF. T.WelshC.QatoD. M.ShahS.GressslerL. E.VivretteR. (2021). Opioid use disorder in pregnancy: Leveraging provider perceptions to inform comprehensive treatment. BMC Health Services Research, 21(1), 215. https://doi.org/10.1186/s12913-021-06182-0
146.
TofighiB.El ShahawyO.SegoshiA.MorenoK. P.BadieiB.SarkerA.KrawczykN. (2020). Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Journal of Addictive Diseases, 39(1), 37–45. https://doi.org/10.1080/10550887.2020.1811456
147.
TofighiB.WilliamsA. R.ChemiC.Suhail-SindhuS.DicksonV.LeeJ. D. (2019). Patient barriers and facilitators to medications for opioid use disorder in primary care. Substance Use & Misuse, 54(14), 2409–2419. https://doi.org/10.1080/10826084.2019.1653324
148.
TriccoA. C.LillieE.ZarinW.O'BrienK. K.ColquhounH.LevacD.MoherD.PetersM. D.HorsleyT.WeeksL.HempelS.AklE. A.ChangC.McGowanJ.StewartL.HartlingL.AldcroftA.WilsonM. G.GarrittyC.StrausS. E. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/M18-0850
149.
TruongC.KrawczykN.DejmanM.Marshall-ShahS.TormohlenK.AgusD.BassJ. (2019). Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addictive Behaviors, 93(Jun), 14–19. https://doi.org/10.1016/j.addbeh.2019.01.020
VailW.FaroE.WatnickD.GiftosJ.FoxA. D. (2021). Does incarceration influence patients’ goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail. Drug and Alcohol Dependence, 222(May), 108529. https://doi.org/10.1016/j.drugalcdep.2021.108529
152.
Van HoutM. C.CrowleyD.McBrideA.DelargyI. (2018). Optimising treatment in opioid dependency in primary care: Results from a national key stakeholder and expert focus group in Ireland. BMC Family Practice, 19(1), 103–108. https://doi.org/10.1186/s12875-018-0792-8
153.
VelasquezM.FlanneryM.BadolatoR.VittitowA.McDonaldR. D.TofighiB.GarmentA. R.GiftosJ.LeeJ. D. (2019). Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addiction Science & Clinical Practice, 14(1), 12–37. https://doi.org/10.1186/s13722-019-0166-0
154.
VennerK. L.DonovanD. M.CampbellA. N.WendtD. C.RieckmannT.RadinS. M.MomperS. L.RosaC. L. (2018). Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addictive Behaviors, 86(Nov), 111–117. https://doi.org/10.1016/j.addbeh.2018.05.017
155.
VineM.StaatzC.BlylerC.BerkJ. (2020). The role of the workforce system in addressing the opioid crisis: A review of the literature. Mathematica Policy Research Reports. (a01ba8436deb4800b7f49b7e973575b2).
156.
WaltersS. M.PerlmanD. C.GuarinoH.Mateu-GelabertP.FrankD. (2022). Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: Benefits of easier access, extended take homes, and new delivery modalities. Substance Use & Misuse, 57(7), 1144–1153. https://doi.org/10.1080/10826084.2022.2064509
157.
WilsonM.FinlayM.OrrM.Barbosa-LeikerC.SheraziN.RobertsM. L. A.LaytonM.RollJ. M. (2018). Engagement in online pain self-management improves pain in adults on medication-assisted behavioral treatment for opioid use disorders. Addictive Behaviors, 86(Nov), 130–137. https://doi.org/10.1016/j.addbeh.2018.04.019
158.
WilsonN.KariisaM.SethP.SmithH.4thDavisN. L. (2020). Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR. Morbidity and mortality weekly report, 69(11), 290–297. https://doi.org/10.15585/mmwr.mm6911a4
159.
WinogradR. P.WoodC. A.StringfellowE. J.PresnallN.DuelloA.HornP.RudderT. (2020). Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment, 108(Jan), 55–64. https://doi.org/10.1016/j.jsat.2019.06.015
160.
ZahraE.ChenR.NielsenS.TranA. D.SantoT.Jr.DegenhardtL.FarrellM.ByrneJ.AliR.LaranceB. (2022). Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. Drug and Alcohol Review, 41(4), 841–850. https://doi.org/10.1111/dar.13437
161.
ZallerN.McKenzieM.FriedmannP. D.GreenT. C.McGowanS.RichJ. D. (2013). Initiation of buprenorphine during incarceration and retention in treatment upon release. Journal of Substance Abuse Treatment, 45(2), 222–226. https://doi.org/10.1016/j.jsat.2013.02.005
162.
ZallerN. D.FuJ. J.BazaziA. R.RichJ. D. (2010). The impact of financial discharge from methadone maintenance therapy on incarceration. Journal of Opioid Management, 6(5), 365–370. https://doi.org/10.5055/jom.2010.0034
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
